Page 5 - Nasdaq Akya News Today : Breaking News, Live Updates & Top Stories | Vimarsana

Stay updated with breaking news from Nasdaq akya. Get real-time updates on events, politics, business, and more. Visit us for reliable news and exclusive interviews.

Top News In Nasdaq Akya Today - Breaking & Trending Today

Akoya Biosciences, Inc. (NASDAQ:AKYA) Receives Consensus Rating of "Buy" from Analysts

Akoya Biosciences, Inc. (NASDAQ:AKYA – Get Rating) has received an average recommendation of “Buy” from the seven analysts that are currently covering the company, MarketBeat reports. Four investment analysts have rated the stock with a buy recommendation. The average twelve-month target price among brokerages that have covered the stock in the last year is $16.17. […] ....

United States , Piper Sandler , Akoya Biosciences , Asia Pacific , American International Group Inc , Jpmorgan Chase Co , Akoya Biosciences Inc , Morgan Stanley , Barclays Plc , Lazard Asset Management , Akoya Biosciences Company Profile , Get Rating , Asset Management , International Group , North America , Middle East , Akoya Biosciences Daily , Nasdaq Akya ,

Akoya Biosciences, Inc. (NASDAQ:AKYA) Sees Large Decrease in Short Interest

Akoya Biosciences, Inc. (NASDAQ:AKYA – Get Rating) saw a significant decrease in short interest during the month of March. As of March 31st, there was short interest totalling 420,900 shares, a decrease of 41.8% from the March 15th total of 722,700 shares. Approximately 2.5% of the company’s stock are sold short. Based on an average […] ....

United States , Asia Pacific , Akoya Biosciences , Piper Sandler , Morgan Stanley , Charles Schwab Investment Management Inc , Akoya Biosciences Inc , Vanguard Group Inc , York Mellon Corp , Blackrock Inc , Get Rating , New York Mellon Corp , Charles Schwab Investment Management , Schwab Investment Management , North America , Middle East , Akoya Biosciences Daily , Nasdaq Akya ,

Stephens Reiterates "Overweight" Rating for Akoya Biosciences (NASDAQ:AKYA)

Stephens reiterated their overweight rating on shares of Akoya Biosciences (NASDAQ:AKYA – Get Rating) in a report released on Tuesday morning, Benzinga reports. They currently have a $16.00 price objective on the stock. Several other research firms also recently commented on AKYA. Piper Sandler dropped their price target on shares of Akoya Biosciences from $17.00 […] ....

United States , Asia Pacific , Akoya Biosciences , Piper Sandler , Vanguard Group Inc , York Mellon Corp , Akoya Biosciences Inc , Akoya Biosciences Company Profile , Charles Schwab Investment Management Inc , Morgan Stanley , Blackrock Inc , Get Rating , New York Mellon Corp , Charles Schwab Investment Management , Schwab Investment Management , North America , Middle East , Akoya Biosciences Daily , Nasdaq Akya , Reiterated Rating ,

Akoya to Report Fourth Quarter and Full Year 2022 Financial

MARLBOROUGH, Mass., Feb. 06, 2023 (GLOBE NEWSWIRE) Akoya Biosciences, Inc. (Nasdaq: AKYA) (“Akoya”), The Spatial Biology Company®, today announced. ....

Priyam Shah , Brian Mckelligon , Akoya Bioscience , Akoya Biosciences , Digital Health , Akoya Biosciences Inc , Spatial Biology Company , Spatial Biology , Life Science , Diagnostic Tools , Annual Cowen Healthcare , Annual Cowen Healthcare Conference , Nasdaq Akya , Akoya Biosciences ,

Akoya to Report Third Quarter 2022 Financial Results on

MARLBOROUGH, Mass., Oct. 11, 2022 (GLOBE NEWSWIRE) Akoya Biosciences, Inc. (Nasdaq: AKYA) (“Akoya”), The Spatial Biology Company®, today announced. ....

Priyam Shah , Akoya Bioscience , Akoya Biosciences , Akoya Biosciences Inc , Spatial Biology Company , Spatial Biology , Nasdaq Akya , Akoya Biosciences ,